Type of ECT influencing toxin removal

- Hemodialysis. This involves the diffusion of the toxin through a semi-permea membrane into the dialysate. ...
- Hemoperfusion. ...
- Hemofiltration. ...
- Peritoneal dialysis (PD) ...
- Continuous renal replacement therapy (CRRT) ...
- Slow low efficiency dialysis (SLED) ...
- Plasmapheresis and plasma exchange.

Peritoneal dialysis (PD) has both advantages and disadvantages, including:

Advantages

- Fewer restrictions: PD has fewer diet and fluid restrictions than hemodialysis.
- Needle-free: PD is needle-free.
- Flexible schedule: PD can be done at home, work, or while traveling, and even while sleeping.
- Continuous therapy: PD provides continuous therapy, which is more similar to how natural kidneys work.
- Longer-lasting kidney function: PD can help preserve kidney function for longer.
- Can be a bridge to a kidney transplant: PD can be a good bridge to a kidney transplant.

Disadvantages

- Requires daily treatment: PD needs to be done every day, which can disrupt your lifestyle.
- Risk of infection: PD can increase the risk of developing peritonitis, an infection of the abdominal membrane.
- Protein levels: The dialysis fluid can reduce protein levels, which can lead to malnutrition and lack of energy.
- Weight gain: Weight gain is a possible side effect.
- Requires skill and knowledge: PD might not be suitable for everyone, as it can require some skill and knowledge to take care of yourself at home.

CONTINUE.....

ADVANTAGES

- Large surface area for cannulation.
- Easy to cannulate
- Little time required for maturation.
- Variety of shapes and configuration
- Easy for surgical implantation.

DISADVANTAGES

- Higher rate of infection
- May reject graft materials
- Higher rate of infection.
- Stenosis at the venous anastomosis, from intimal hyperplasia.
- No development of collateral circulation.



Hepatic clearance is **the amount of blood that passes through the liver and is cleared of a substance over a given amount of time**. It's a measure of the liver's ability to extract and metabolize a substance, such as a drug, as it passes through the liver.

Hepatic clearance is influenced by a number of factors, including:

- Hepatic blood flow: The amount of blood that flows through the liver
- Protein binding: How much of the substance is bound to protein
- Liver enzyme activity: The ability of the liver's enzymes to metabolize the substance

Definition:

- **Pharmacogenetics** is the study of inherited genetic differences in drug metabolic pathways which can affect individual responses to drugs, both in terms of therapeutic effect as well as adverse effects.

The CYP2D6 gene is highly polymorphic, with **more than 100 allelic variants**, and is one of the most important enzymes involved in drug metabolism. The variants can affect the enzyme's activity, and can lead to different responses to certain drugs.

Here are some things to know about CYP2D6 genetic polymorphisms:

Allelic variants

There are many different allelic variants of CYP2D6, including SNPs, gene deletions, and duplications.

Phenotypes

Variant alleles are classified into phenotypes based on enzymatic activity. For example, the ultrarapid phenotype is associated with multiple copies of CYP2D61, CYP2D62, or CYP2D6*35.

Allele frequency

The alleles of importance may vary between populations. For example, in Caucasians, the allele frequency for the *3,

The CYP2D6 gene is **highly polymorphic, with more than 100 allelic variants**, including:

- CYP2D61, CYP2D62, or CYP2D635*: Multiple copies of these alleles can cause an ultrarapid (ultrametabolizer, UM) phenotype.
- CYP2D63*: A frameshift mutation that inactivates CYP2D6.
- CYP2D64*: A splicing defect that inactivates CYP2D6.
- CYP2D610*: A nonsynonymous polymorphism that reduces CYP2D6 catalytic activity. This allele is highly prevalent in Asia.
- CYP2D614*: A nonsynonymous polymorphism that reduces CYP2D6 catalytic activity. This allele is predominantly found in individuals with African ancestry.

Genetic polymorphisms in the cytochrome P450 2C9 (CYP2C9) enzyme **can affect the metabolism of drugs and can have clinical consequences**:

Drug toxicity

Genetic polymorphisms can affect the toxicity of drugs that have lower therapeutic indices, such as warfarin, phenytoin, and some antidiabetic drugs.

Drug metabolism

Polymorphisms can affect drug bioavailability and systemic clearance. For example, in people with multiple CYP2C9 polymorphisms, warfarin metabolism can be very slow, which can lead to an overdose.

Lung cancer

CYP2C9 plays a role in metabolizing benzo[a]pyrene, a major lung carcinogen, so genetic polymorphisms may affect susceptibility to lung cancer.

Ethnic differences

The distribution of CYP2C9 alleles varies between ethnic groups. For example, the

Efflux Transporters in the Intestine

In the intestine, drug-transporter interactions involving the efflux transporters often result in poor absorption and **low oral bioavailability** as the drug is readily effluxed back into the intestinal lumen and excreted out of the body.

Genetic polymorphisms can affect how a person responds to a drug, and some examples include:

Glutathione S-transferase (GST) enzyme

Polymorphisms in the GST enzyme can alter the metabolism of chemotherapeutic drugs, which can impact the effectiveness of cancer treatments.

Cytochromes P450 (CYP)

Polymorphisms in the CYP genes can significantly impact how a person responds to a drug. The most clinically relevant CYP polymorphisms are in CYP2D6, CYP2C9, and CYP2C19.

GPCRs

Genetic variation in GPCRs can occur in functional sites, such as ligand binding, effector binding, and activation micro-switches. Some examples of GPCRs with high levels of variation include the somatostatin SST receptor, cholecystokinin A receptor, dopamine D receptor, and calcitonin receptor.

Some examples of clinically important polymorphisms of drug transporters include:



OATP1B1

A hepatic drug uptake transporter that is highly polymorphic. Polymorphisms in this transporter can affect the ability of the liver to uptake and clear drugs, which can lead to reduced drug clearance. For example, the Val174Ala polymorphism in the SLCO1B1 gene can increase plasma concentrations of simvastatin acid, which can increase the risk of simvastatin-induced myopathy.

CYP2D6

A cytochrome P450 enzyme that metabolizes many drugs. The CYP2D6 gene is highly polymorphic, and allelic variants can cause a large variation in enzymatic activity.

CYP2C19

A polymorphic isoenzyme in the cytochrome P450 system that metabolizes several drugs, including proton-pump inhibitors.



ABCC1

A lipophilic anion pump that can confer resistance to anti-cancer drugs.

Genetic polymorphisms, or common genetic variants, can impact how a person responds to drugs in several ways, including:

Drug metabolism

Genetic variations in drug-metabolizing enzymes can cause different subgroups of people to have different abilities to process drugs. For example, some people metabolize drugs slowly, which can cause the drug to build up in the body and become toxic. Others metabolize drugs so quickly that the drug levels in their blood never reach high enough levels to be effective.

Drug distribution and excretion

Genetic polymorphisms in drug transporter genes can change how drugs are distributed and excreted in the body.

Drug target sensitivity

Genetic variations can affect how sensitive drug targets are to drugs.

Clinical response

Genetic polymorphisms can change gene expression or activity, which can lead to different clinical responses to drugs.

What is an adaptive method?

Introduction of adaptive methods: Adaptive methods are **used by some methods to determine the boundaries or characteristic frequencies in the frequency domain, adapting to different signal characteristics and environmental conditions.**

What is population pharmacokinetic?

In population pharmacokinetics opportunistic samples are collected from actual patients taking a drug. Population pharmacokinetic studies **aim to identify and quantify sources of variability in drug concentration in the patient population**.

Advantages of Population pharmacokinetics

- Provides better understanding of the dose-response relationship among the target population.
- Sample population mimics the real target population at large.
- Multiple factors may be studied in one population PK study.
- Diversity of patient characteristics and larger sample sizes.
- Prior dose adjustment can be made using Population PK data.

Traditional Pharmacokinetic Studies

- Involve taking ***multiple blood samples*** periodically over time
- in a *few individual patients*, and
- characterizing ***basic pharmacokinetic parameters*** such as k, VD, and Cl.
- Because the studies are generally well designed, there are fewer parameters than data points.
- Traditional pharmacokinetic parameter estimation is very ***accurate***, provided that enough samples can be taken for the individual patient.
- The disadvantage is that only a few relatively homogeneous healthy subjects are included in pharmacokinetic studies, from which dosing in different patients must be projected.

Meaning of interindividual in English

between single people or things:

There is considerable interindividual variation in the response to the treatment. About 50% of this inter-individual variability is determined by the effect of genes. We will concentrate on interindividual similarities and differences.

Interindividual studies are **studies that involve or take place between individuals**:

Interindividual differences

Differences between people, such as how some people are shyer than others, take more risks, or are more attracted to immediate gains.

Interindividual variability

Variability in responses between individuals, such as in clinical interventions like rTMS for depression.

Interindividual differences in perception

Differences in perception between people, such as optical illusions, auditory illusions, and the effect of culture on perception.

Interindividual differences in economics

Differences that can help lessen multicollinearity in time series data, which can help determine the individual influences of each explanatory variable.

Within-subject variation is **when an individual acts differently in the same situation at different times**. It's one of three components of variability in longitudinal processes, along with between-subjects variability and random errors.

Within-subject variation can be used to make inferences about a single subject's responses, but these inferences are different from those about the population the subject came from.

Random error is a type of measurement error that can occur in population pharmacokinetics:

Definition

Random error is a type of measurement error that occurs due to natural variability in the measurement process. It's unpredictable and can occur equally in both directions, relative to the correct value.

Impact

Random error can impact the validity of study results.

Minimization

Random error can be minimized by increasing sample size, studying a more homogeneous population, or using more precise measurement tools.

Modeling

In modeling, random effects act like additional error terms, and their distributions and covariances must be specified.

Comparison to measurement error

Measurement error gives rise to uncorrelated errors at different measurement times within an

In population pharmacokinetics, residual error, also called **residual unexplained variability**, is an important consideration when modeling data. Here are some things to know about residual error in population pharmacokinetics:

Combined proportional and additive residual error model

This model is often used because it describes data better than a proportional or additive error model alone. It assumes that the variance of the residual error is the sum of two independent components.

Replication error plus pure residual (assay) error

This model acknowledges two separate sources of residual error. Simulation results suggest that ignoring these separate sources of error doesn't adversely affect parameter estimates.

Exponential and proportional models

These models are generally avoided because they tend to "overweight" low concentrations.

Additive residual error

This model may be sufficient for pharmacodynamic data, which often have

What is the value of pharmacokinetics?

Clinical Significance

Pharmacokinetics, as a field, **attempts to summarize the movement of drugs throughout the body and the actions of the body on the drug**. By using the above terms, theories, and equations, practitioners can better estimate the locations and concentrations of a drug in different areas of the body.

PHARMACOKINETIC MODEL EVALUATION

- Two pharmacokinetic (PK) models were evaluated and compared for population approach using WinNonlin.

A. 1-compartment model without lag time
B. 1-compartment model with lag time
C. 2-compartment model without lag time
D. 2-compartment model with lag time

Afterwards, Akaike's Information Criteria (AIC), condition number, frequency of changing +/– signs (runs) and CV% were mainly used to determine the model that most adequately described the levosulpiride and terbinafine data.

What are the methods of pharmacokinetics?

There are four main components of pharmacokinetics: **liberation, absorption, distribution, metabolism and excretion (LADME)**. These are used to explain the various characteristics of different drugs in the body. They are covered in more detail below.

Mostly known PBPK software include **Simcyp, PKSIM, Gastroplus, ADMEWORKS, DDI simulators**, etc can be usedto simulate pharmacokinetic profiles in virtual patients, to predict possible drug–drug interaction, extrapolate data from preclinical models to human, simulate human plasma concentration time profile from in vitro ...

Formula

$$P(A \mid B) = \frac{P(B \mid A) \cdot P(A)}{P(B)}$$

A, B = events

$P(A|B)$ = probability of A given B is true

$P(B|A)$ = probability of B given A is true

$P(A), P(B)$ = the independent probabilities of A and B